SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-313928"
 

Search: onr:"swepub:oai:DiVA.org:uu-313928" > Anticoagulation the...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Guimaraes, Patricia O.Duke Hlth, Duke Clin Res Inst, Durham, NC 27705 USA. (author)

Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation : Insights from the ARISTOTLE trial

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • Elsevier BV,2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-313928
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-313928URI
  • https://doi.org/10.1016/j.ijcard.2016.11.014DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Evidence supporting use of antithrombotic therapy in atrial fibrillation (AF) is based mainly on data from patients with permanent, persistent, or paroxysmal AF. Less is known about the risk following a new diagnosis of AF and the efficacy and safety of apixaban in these patients. Methods: Using data from ARISTOTLE, we assessed the relationship between timing of AF diagnosis and clinical outcomes and the efficacy and safety of apixaban versus warfarin in these patients. Recently diagnosed AF was defined as a new diagnosis of AF within 30 days prior to enrollment. Cox proportional hazards models were used to determine the association between recently diagnosed AF and clinical outcomes. We also assessed the efficacy and safety of apixaban versus warfarin according to time since AF diagnosis. Results: In ARISTOTLE, 1899 (10.5%) patients had recently diagnosed AF. After adjustment, patients with recently versus remotely diagnosed Al' had a similar risk of stroke/systemic embolism (HR = 1.07, 95% CI = 0.80-1.42; p 0.67), but higher mortality was seen in patients with recently diagnosed AF (adjusted HR = 1.21, 95% Cl 1.02-1.43; p 0.03). The beneficial effects of apixaban, compared with warfarin, on clinical outcomes were consistent, irrespective of timing of AI' diagnosis (all interaction p-values >0.12). Conclusion: Patients with recently diagnosed AF had a similar risk of stroke but higher mortality than patients with remotely diagnosed AF, suggesting that they are not at "low risk" and warrant stroke prevention strategies. The benefits of apixaban over warfarin were preserved, irrespective of timing of AF diagnosis.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Wojdyla, Daniel M.Duke Hlth, Duke Clin Res Inst, Durham, NC 27705 USA. (author)
  • Alexander, John H.Duke Hlth, Duke Clin Res Inst, Durham, NC 27705 USA. (author)
  • Thomas, LaineDuke Hlth, Duke Clin Res Inst, Durham, NC 27705 USA. (author)
  • Alings, MarcoWorking Grp Cardiovasc Res, Utrecht, Netherlands.;Julius Clin, Zeist, Netherlands. (author)
  • Flaker, Greg C.Univ Missouri, Sch Med, Columbia, MO USA. (author)
  • Al-Khatib, Sana M.Duke Hlth, Duke Clin Res Inst, Durham, NC 27705 USA. (author)
  • Hanna, MichaelBristol Myers Squibb, Princeton, NJ USA. (author)
  • Horowitz, John D.Univ Adelaide, Queen Elizabeth Hosp, Cardiol Unit, Adelaide, SA, Australia. (author)
  • Wallentin, LarsUppsala universitet,Uppsala kliniska forskningscentrum (UCR),.(Swepub:uu)larswall (author)
  • Granger, Christopher B.Duke Hlth, Duke Clin Res Inst, Durham, NC 27705 USA. (author)
  • Lopes, Renato D.Duke Hlth, Duke Clin Res Inst, Durham, NC 27705 USA. (author)
  • Duke Hlth, Duke Clin Res Inst, Durham, NC 27705 USA.Working Grp Cardiovasc Res, Utrecht, Netherlands.;Julius Clin, Zeist, Netherlands. (creator_code:org_t)

Related titles

  • In:International Journal of Cardiology: Elsevier BV227, s. 443-4490167-52731874-1754

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view